Spots Global Cancer Trial Database for Study of CEP-701 in Treatment of Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of CEP-701 in Treatment of Prostate Cancer

Official Title: An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen

Study ID: NCT00081601

Conditions

Prostate Cancer

Interventions

CEP-701

Study Description

Brief Summary: The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.

Detailed Description: A serological PSA response is defined as a reduction from baseline PSA serum concentration of at least 50%, which is confirmed by a second PSA value 28 or more days later.